BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for vaccine candidates Thursday, including one from Inovio which received a CEPI grant to fund a Korean trial.

The majority of clinical COVID-19 programs are sponsored by industry, like Inovio’s vaccine, with only two trials, including one for Moderna’s vaccine, government-sponsored (see Daily Chart)...